Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Almotriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 4/20 | 0.65 |
| ▸ | HTR1B known ✓ | P28222 | 4/20 | 0.65 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 7/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 11/20 | 0.65 |
| ▸ | HTR7 | P34969 | 2/20 | 0.65 |
| ▸ | HTR2C | P28335 | 2/20 | 0.65 |
| ▸ | HTR1E | P28566 | 1/20 | 0.65 |
| ▸ | HTR3A | P46098 | 1/20 | 0.65 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Almotriptan SCHEMBL1957 | 1.00 | HTR1A (1.00) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL29396422 | 1.00 | HTR1A (1.00) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| SCHEMBL1437 | 0.99 | HTR1A (0.98) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL2166 | 0.99 | HTR1A (0.98) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Hydrochloric Acid SCHEMBL2312 | 0.98 | HTR1A (0.96) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL5042399 | 0.98 | HTR1A (0.96) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL1774275 | 0.95 | HTR1A (0.90) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL2761861 | 0.93 | HTR1A (0.86) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL6444414 | 0.93 | HTR1A (0.86) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL221132 | 0.92 | HTR1A (0.85) | HTR1AHTR2AHTR2BLMNAADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2490669-B1 | TRIPTANS FOR THE TREATMENT OF PSORIASIS | FORTUDERM LTD (IL) | 2017-01-11 | — | — | EP | disclosed |
| US-20140155443-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR PSORIASIS | DASCALU AVI (IL) | 2014-06-05 | — | — | US | disclosed |
| US-8680134-B2 | Triptans for the treatment of psoriasis | DASCALU AVI (IL) | 2014-03-25 | — | — | US | disclosed |
| WO-2014024193-A1 | COMPOSITIONS AND METHODS FOR RAPID TRANSMUCOSAL DELIVERY OF PHARMACEUTICAL INGREDIENTS | PRODEL PHARMA LTD. (IL) | 2014-02-13 | — | — | WO | disclosed |
| US-20120252863-A1 | TRIPTANS FOR THE TREATMENT OF PSORIASIS | DASCALU AVI (IL) | 2012-10-04 | — | — | US | disclosed |
| US-20100086495-A1 | COMPOSITIONS AND METHODS FOR ENHANCING TRANSMUCOSAL DELIVERY | DERMA-YOUNG LTD. (IL) | 2010-04-08 | — | — | US | disclosed |
| EP-2114384-A2 | COMPOSITIONS AND METHODS FOR ENHANCING TRANSMUCOSAL DELIVERY | Derma-Young Ltd. (IL) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008099397-A2 | COMPOSITIONS AND METHODS FOR ENHANCING TRANSMUCOSAL DELIVERY | DERMA-YOUNG LTD. (IL) | 2008-08-21 | — | — | WO | disclosed |